RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

Relief Therapeutics Holding SA / Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

27-Jun-2024 / 12:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
of Shareholders

GENEVA (June 27, 2024) - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB:
RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical
company committed to delivering innovative treatment options for select
specialty, unmet and rare diseases, announces the results of its annual
general meeting (AGM) of shareholders, which took place in Geneva today. All
but one of the proposed resolutions were approved by a large majority of the
represented votes.

AGM results

1. Annual Report and Financial Statements for the Year 2023

The AGM approved the 2023 annual report and financial statements.

2. Appropriation of Results

The AGM approved carrying forward the loss for the financial year 2023.

3. Discharge of the Board of Directors and the Executive Committee

The AGM did not grant discharge to the board of directors and the executive
committee for the financial year 2023. While the extraordinary general
meeting earlier this year granted such discharge for that period, the
Company acknowledges this outcome and will continue to engage with
shareholders to address their concerns.

  4.  Compensation of the members of the Board of Directors and of the
    Executive Committee

The AGM approved the proposed maximum total amounts for compensation of the
board of directors for the period from this AGM 2024 until the AGM 2025, and
of the executive committee for the financial year 2025. The AGM also
approved, on a consultive basis, the 2023 compensation report.

5. Elections

1. Members of the Board of Directors

The AGM re-elected Dr. Raghuram Selvaraju, Mr. Peter de Svastich, Mr.
Gregory Van Beek, and Mr. Thomas Elzinga to the board of directors. As
previously announced, Ms. Michelle Lock did not stand for re-election,
ending her service on the board of directors today.

2. Chairman of the Board of Directors

The AGM approved the re-election of the chairman of the board of directors,
Dr. Raghuram Selvaraju.

3. Nomination and Compensation Committee

The AGM approved the election of Mr. Peter de Svastich and the re-election
of Dr. Raghuram Selvaraju as members of the nomination and compensation
committee.

4. Independent Voting Rights Representative

The AGM approved the re-election of the independent proxy, Mr. Thomas Hua.

5. Auditors

The AGM approved the re-election of the statutory auditor, MAZARS SA.


The resolutions submitted for the shareholders' vote are detailed in the AGM
Invitation. The voting results will be made available on the Company's
website later today.

ABOUT RELIEF THERAPEUTICS
Relief Therapeutics is a commercial-stage biopharmaceutical company
committed to advancing treatment paradigms and delivering improvements in
efficacy, safety, and convenience to benefit the lives of patients living
with select specialty and rare diseases. Relief Therapeutics' portfolio
offers a balanced mix of marketed, revenue-generating products, our
proprietary, globally patented TEHCLO(TM) and Physiomimic(TM) platform
technologies and a targeted clinical development pipeline consisting of
risk-mitigated assets focused in three core therapeutic areas: rare skin
diseases, rare metabolic disorders, and rare respiratory diseases. In
addition, Relief Therapeutics is commercializing several legacy products via
licensing and distribution partners. Headquartered in Geneva, Relief
Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and
quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more
information, please visit our website www.relieftherapeutics.com.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
contact@relieftherapeutics.com

DISCLAIMER
This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties, including its
ability to achieve its corporate, development and commercial goals, and
other factors which could cause the actual results, financial condition,
performance or achievements of Relief Therapeutics to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. A number of factors, including
those described in Relief Therapeutics' filings with the SIX Swiss Exchange
and the U.S. Securities and Exchange Commission (SEC), could adversely
affect Relief Therapeutics. Copies of Relief Therapeutics' filings with the
SEC are available on the SEC EDGAR database at www.sec.gov. Relief
Therapeutics does not undertake any obligation to update the information
contained herein, which speaks only as of this date.

Additional features:


File: https://eqs-cockpit.com/c/fncls.ssp?u=0662a9c5b4bac180f3429530c6af0806
File description: Ad hoc

---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Relief Therapeutics Holding SA
                   Avenue de Secheron 15
                   1202 Geneva
                   Switzerland
   Phone:          +41 22 545 11 16
   E-mail:         contact@relieftherapeutics.com
   Internet:       https://relieftherapeutics.com
   ISIN:           CH0100191136
   Valor:          10019113
   Listed:         SIX Swiss Exchange
   EQS News ID:    1934193

End of Announcement EQS News Service
---------------------------------------------------------------------------

1934193 27-Jun-2024 CET/CEST